Navigation Links
A step forward in the treatment of chronic urticaria
Date:3/20/2013

This press release is available in Spanish.

Barcelona, 20th March 2013.- An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

Spontaneous chronic urticaria, one of the most common skin diseases, consists of an abrupt reaction that results in hives or stains of different shapes and sizes on the surface of the skin that grow and produce a very intense itch. Sufferers can develop dozens of hives each day for months or years. When the condition persists for more than 6 weeks, it is referred to as chronic urticaria and can last between approximately 5 and 10 years, adversely affecting the quality of life of the sufferer in both physical and emotional terms.

Approximately 50% of urticaria patients do not respond to treatment with standard doses of non-sedative antihistamines, and require a heavier dose of antihistamines. Some people even require immunosupressors, such as corticoids and cyclosporine A, to control the condition. These immunosupressors have significant side effects.

The study, in which Dr. Ana Gimnez Arnau, a dermatologist at the Hospital del Mar and researcher with the group conducting research on inflammatory dermatological diseases at the IMIM (Hospital del Mar Medical Research Institute) was involved alongside institutions from Germany, the United States, and the United Kingdom, demonstrated that Omalizumab, a biological treatment that prevents immunoglobulin E from joining up with the receptor of the cells that triggers the urticaria, the mast cell, radically eliminates clinical symptoms (itching) and signs of urticaria (hives) in patients for whom antihistamines are ineffective.

The research, which has consisted of an international Phase III clinical trial conducted across several centres of research, has run for 7 months and involved 323 patients from different countries. These patients have an average age of 42 and for the most part are women (76%), a description that accurately reflects the profile of patients with chronic urticaria.

At 4-week intervals over a period of three months, participants were randomly given doses of 75,150, and 300mg of Omalizumab or a placebo drug using the double-blind method and their condition monitored. "In week 12, we can see a significant difference between the groups that receive doses of 150mg or 300mg of Omalizumab and those who receive a dose of 75mg or the placebo drug. The itching and the urticaria totally disappeared in 23% of patients administered a dose of 150mg, and in 53% of patients administered 300mg of Omalizumab", explains Dr. Gimnez Arnau. She also adds that "the therapeutic objective is the full remission of symptoms in order to continue the therapy over a number of months before gradually phasing it out, resulting in the complete elimination of the disease".

This drug, for which US and European authorities will begin the registration process for treating this condition, is superior to the immunosupressors currently used to treat serious cases in its very fast effectiveness in 90% of patients and ease of use (once a month), as well as the fact that it has many fewer side effects. If registered, it could be available for use in treating chronic urticaria in 2014.

This is the first of three international clinical trials and, while the results thus far are very promising, further research is required to determine the exact role of this drug, its possible side effects, and the doses to be administered. This research gives hope to many people who have been waiting years for a solution, people who suffer with chronic urticaria on a daily basis and whose quality of life is greatly affected by the condition (itching, sleeplessness, psychiatric problems such as anxiety or depression), and a hope of eliminating the socioeconomic impact of the disease for society, since sufferers of chronic urticaria require constant medication to control the symptoms of their condition.


'/>"/>

Contact: Marta Calsina
mcalsina@imim.es
34-933-160-680
IMIM (Hospital del Mar Medical Research Institute)
Source:Eurekalert

Related medicine news :

1. Corporate Whistle Blower Center Now Urges Insiders to Step Forward if They Have Proof a Medical Device Maker Knew About Failures & Continued to Sell the Product-Rewards
2. Corporate Whistle Blower Center Now Urges Employees of Any Type Of Private Contractor in Afghanistan or Iraq to Step Forward for Rewards if They Possess Proof of Fraud
3. Retina Specialty Institute Gives Patients Something to Look Forward to in Crestview
4. DePuy ASR Hip Recall, Transvaginal Mesh Lawsuit Updates: Bernstein Liebhard LLP Looks Forward to Start of First Bellwether Trials in New Year
5. Propecia Lawsuits Being Investigated by Bernstein Liebhard LLP, as Propecia Litigation Pending in New Jersey Superior Court Continues to Move Forward
6. Massage School San Diego Names Step Forward Pick of the Week as RAW One
7. Rectal microbicide research takes giant leap forward with groundbreaking educational video
8. Attorney Deborah Truhowsky Featured On “Paying It Forward” Internet Broadcast Program
9. GiveForward.com Helps Launch Online Campaign to Help Sick Single Mom in Need
10. University of Pennsylvania Medicine receives National Institutes of Health grant to help local communities move forward after asbestos exposure
11. A leap forward in the quest to develop an artificial pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Maryland (PRWEB) , ... December 09, 2016 , ... ... digital whiteboard display solutions, proudly announced today that a new solution for Emergency ... to fit in the tight space in Emergency Department examination rooms, and with ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... program through the Pennsylvania Cable Network (PCN) during the summer of 2016. The ... Implementation Grant provided by the United States Department of Health and Human Services ...
(Date:12/8/2016)... ... 2016 , ... The Florida Hospital Tampa Wound Healing Institute ... (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute as ... facilities have earned this distinction. This is the second time the Florida Hospital ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer ... our first franchise-wide Quack Gives Back initiative, and we’re very pleased ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... NORWALK, Connecticut , 8 de dezembro de 2016  A Mederi ... a terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico ... Reading ... Live Stretta procedure performed ... Director of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
Breaking Medicine Technology: